Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Immuneering Corporation

35 indications, side-by-side phase, drug & LoA

$4.19

+0.07 (+1.7%)

C 47Pipeline Score Undervalued Pharma · Clinical
Market Cap
348.72 M
EPS
-1.17
P/E Ratio
-
Value Trade
8.67 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • R&D Expenses

    10.65 M

  • Operating CF

    -18.43 M

  • Total Assets

    214.81 M

  • Total Liabilities

    8.29 M

  • Equity

    206.52 M

  • D/E Ratio

    12,345

5.69 %
Week
-3.58 %
1 Month
2.67 %
3 Month
-22.45 %
6 Month
-72.36 %
5 Year
-72.36 %
All Time
Cash Data
Healthy

  • Cash Position

    198.64 M

  • Monthly Burn

    6.14 M

  • Runway

    31.4 mo

  • Burn Trend

    Accelerating

  • SEC Filing

    May 15, 2026
Overview
Volume
1.55 M
52 Week Range
1.56 - 10.08
% held by Insiders
13.67 %
% held by Institutions
46.96 %
Enterprise Value
195.75 M
Total Shares
64.56 M
Short %
34.7 %
Float Shares
36.67 M
Company Description
HQ: 245 MAIN STREET, SECOND FLOOR,...
Employees:55
https://www.immuneering.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
C47
Pipeline Score
$1.3B
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
3.8x
rNPV / MCap
Top 72%
Micro Cap
(rank 254 of 905)
Percentile Rank
Immuneering Corporation carries a moderate pipeline score (47/100), with $3.3B risk-adjusted pipeline value, led by IMM-1-104 Monotherapy in Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
IMM-6-415
Small molecule		Advanced Solid Tumor (Phase 1)Phase 1NCT062081245% $1.6B COMPLETED 30 - -Apr 30, 2025 -May 28, 2025
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
atebimetinib (IMM-1-104)
pancreatic cancer
Phase 2a
2025-07-10
atebimetinib (IMM-1-104)
pancreatic cancer
Phase 2a
2025-07-10
atebimetinib (IMM-1-104)
pancreatic cancer
Phase 2a
2025-07-10
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in IMRX
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
IMRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
IMRX
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
IMRX Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
IMRX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
2026-07-17 0.00 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Immuneering Corporation (IMRX) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How IMRX ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Pancreatic Cancer #8 of 72 PHASE 3 Atebimetinib + GnP + mGnP
RVMD RCUS AZN
$3.7B 0.82 CONTENDER
Melanoma #34 of 52 PHASE 1 IMM-1-104 Monotherapy
MRK BMY REGN
$10.5B 0.82 FOLLOWER
Non-Small Cell Lung Cancer #57 of 88 PHASE 1 IMM-1-104 Monotherapy
MRK AZN RVMD
$28.1B 0.82 FOLLOWER